<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296890</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN853-0417</org_study_id>
    <secondary_id>2020-000179-19</secondary_id>
    <nct_id>NCT04296890</nct_id>
  </id_info>
  <brief_title>A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</brief_title>
  <acronym>SORAYA</acronym>
  <official_title>SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine&#xD;
      (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer,&#xD;
      primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate&#xD;
      Receptor-Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for&#xD;
      single-agent therapy for their next line of therapy. All patients will receive single-agent&#xD;
      MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine&#xD;
      (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer,&#xD;
      primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate&#xD;
      Receptor Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for&#xD;
      single-agent therapy for their next line of therapy. FRα positivity will be defined by the&#xD;
      Ventana FOLR1 (Folate Receptor 1/Folate Receptor Alpha) Assay.&#xD;
&#xD;
      Approximately 110 eligible patients will be enrolled to achieve a total of 105 efficacy&#xD;
      evaluable patients. Efficacy evaluable patients include those who have measurable lesions per&#xD;
      Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) at baseline and&#xD;
      received at least 1 dose of MIRV.&#xD;
&#xD;
      All patients will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight (AIBW)&#xD;
      administered on Day 1 of every 3-week cycle (Q3W).&#xD;
&#xD;
      Tumor response will be evaluated by the Investigator using RECIST v1.1. Computerized&#xD;
      tomography (CT) or magnetic resonance imaging (MRI) scans will be collected for sensitivity&#xD;
      analysis by blinded independent central review (BICR).&#xD;
&#xD;
      Patients will continue to receive MIRV until disease progression, unacceptable toxicity,&#xD;
      withdrawal of consent, death, or until the Sponsor terminates the study (whichever comes&#xD;
      first).&#xD;
&#xD;
      Tumor assessments, including radiological assessments by CT/MRI scans will be performed at&#xD;
      Screening and subsequently every 6 weeks (± 1 week) from Cycle 1 Day 1 (C1D1) for the first&#xD;
      36 weeks then every 12 weeks (± 3 weeks) until disease progression, death, the start of new&#xD;
      anticancer therapy, or patient's withdrawal of consent (whichever occurs first).&#xD;
&#xD;
      Patients who discontinue MIRV for reasons other than progressive disease (PD) will continue&#xD;
      with tumor assessments until documentation of PD or the start of a new anticancer therapy,&#xD;
      whichever comes first. Prior to Week 36 (from Cycle 1, Day 1), assessments should occur every&#xD;
      6 weeks (± 1 week) as allowed by local requirements but must occur at an interval of no more&#xD;
      than 12 weeks. After Week 36, assessment will occur every 12 weeks (± 3 weeks) until&#xD;
      documentation of PD or the start of new anticancer therapy.&#xD;
&#xD;
      All patients who discontinue MIRV will be followed for survival every 3 months (± 1 month)&#xD;
      until death, lost to follow-up, withdrawal of consent for survival follow-up, or end of study&#xD;
      (EOS) (whichever comes first). Additional survival follow-up calls may occur periodically, if&#xD;
      needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the Investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from initial Investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AE's will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from first dose of MIRV until Investigator-assessed radiological progressive disease (PD) or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from first dose of MIRV until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum CA-125 response determined using the Gynecologic Cancer Intergroup (GCIG) criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab Soravtansine</intervention_name>
    <description>Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>IMGN853</other_name>
    <other_name>MIRV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥ 18 years of age&#xD;
&#xD;
          2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian&#xD;
             cancer (EOC), primary peritoneal cancer, or fallopian tube cancer&#xD;
&#xD;
          3. Patients must have platinum-resistant disease:&#xD;
&#xD;
               1. Patients who have only had 1 line of platinum based therapy must have received at&#xD;
                  least 4 cycles of platinum, must have had a response (complete response/remission&#xD;
                  (CR) or partial response/remission (PR)) and then progressed between &gt; 3 months&#xD;
                  and ≤ 6 months after the date of the last dose of platinum&#xD;
&#xD;
               2. Patients who have received 2 or 3 lines of platinum therapy must have progressed&#xD;
                  on or within 6 months after the date of the last dose of platinum&#xD;
&#xD;
             Note: Progression should be calculated from the date of the last administered dose of&#xD;
             platinum therapy to the date of the radiographic imaging showing progression&#xD;
&#xD;
             Note: Patients who are platinum refractory during front-line treatment are excluded&#xD;
             (see exclusion criteria)&#xD;
&#xD;
          4. Patients must have progressed radiographically on or after their most recent line of&#xD;
             anticancer therapy.&#xD;
&#xD;
          5. Patients must be willing to provide an archival tumor tissue block or slides, or&#xD;
             undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure&#xD;
             for immunohistochemistry (IHC) confirmation of Folate Receptor α (FRα) positivity&#xD;
&#xD;
          6. Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1&#xD;
             Assay&#xD;
&#xD;
          7. Patients must have at least 1 lesion that meets the definition of measurable disease&#xD;
             by RECIST v1.1 (radiologically measured by the Investigator)&#xD;
&#xD;
          8. Patients must have received at least 1 but no more than 3 prior systemic lines of&#xD;
             anticancer therapy, including at least 1 line of therapy containing bevacizumab, and&#xD;
             for whom single-agent therapy is appropriate as the next line of treatment:&#xD;
&#xD;
               1. Adjuvant ± neoadjuvant considered 1 line of therapy&#xD;
&#xD;
               2. Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose&#xD;
                  polymerase (PARP) inhibitors) will be considered part of the preceding line of&#xD;
                  therapy (i.e., not counted independently)&#xD;
&#xD;
               3. Therapy changed due to toxicity in the absence of progression will be considered&#xD;
                  part of the same line (i.e., not counted independently)&#xD;
&#xD;
               4. Hormonal therapy will be counted as a separate line of therapy unless it was&#xD;
                  given as maintenance&#xD;
&#xD;
          9. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)&#xD;
             of 0 or 1&#xD;
&#xD;
         10. Patients must have completed prior therapy within the specified times below:&#xD;
&#xD;
               1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is&#xD;
                  shorter) prior to first dose of MIRV&#xD;
&#xD;
               2. Focal radiation completed at least 2 weeks prior to first dose of MIRV&#xD;
&#xD;
         11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior&#xD;
             therapy-related toxicities (except alopecia)&#xD;
&#xD;
         12. Patients must have completed any major surgery at least 4 weeks prior to first dose of&#xD;
             MIRV and have recovered or stabilized from the side effects of prior surgery&#xD;
&#xD;
         13. Patients must have adequate hematologic, liver and kidney functions defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500/μL) without G-CSF in the&#xD;
                  prior 10 days or long-acting WBC growth factors in the prior 20 days&#xD;
&#xD;
               2. Platelet count ≥ 100 x 10^9/L (100,000/μL) without platelet transfusion in the&#xD;
                  prior 10 days&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the&#xD;
                  prior 21 days&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN&#xD;
&#xD;
               6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert&#xD;
                  syndrome are eligible if total bilirubin &lt; 3.0 x ULN)&#xD;
&#xD;
               7. Serum albumin ≥ 2 g/dL&#xD;
&#xD;
         14. Patients or their legally authorized representative must be willing and able to sign&#xD;
             the informed consent form (ICF) and to adhere to the protocol requirements&#xD;
&#xD;
         15. Women of childbearing potential (WCBP) must agree to use highly effective&#xD;
             contraceptive method(s) (as defined in Section 5.8.6 of the protocol) while on MIRV&#xD;
             and for at least 3 months after the last dose&#xD;
&#xD;
         16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of&#xD;
             MIRV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male patients&#xD;
&#xD;
          2. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed&#xD;
             tumors containing any of the above histologies, or low-grade/borderline ovarian tumor&#xD;
&#xD;
          3. Patients with primary platinum-refractory disease, defined as disease that did not&#xD;
             respond to (CR or PR) or has progressed within 3 months of the last dose of first-line&#xD;
             platinum-containing chemotherapy&#xD;
&#xD;
          4. Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the&#xD;
             bone marrow&#xD;
&#xD;
          5. Patients with &gt; Grade 1 peripheral neuropathy per Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE)&#xD;
&#xD;
          6. Patients with active or chronic corneal disorders, history of corneal transplantation,&#xD;
             or active ocular conditions requiring ongoing treatment/monitoring, such as&#xD;
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal&#xD;
             injections, active diabetic retinopathy with macular edema, macular degeneration,&#xD;
             presence of papilledema, and /or monocular vision&#xD;
&#xD;
          7. Patients with serious concurrent illness or clinically relevant active infection,&#xD;
             including, but not limited to the following:&#xD;
&#xD;
               1. Active hepatitis B or C infection (whether or not on active antiviral therapy)&#xD;
&#xD;
               2. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
               3. Active cytomegalovirus infection&#xD;
&#xD;
               4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks&#xD;
                  prior to the first dose of MIRV&#xD;
&#xD;
             Note: Testing at screening is not required for the above infections unless clinically&#xD;
             indicated&#xD;
&#xD;
          8. Patients with a history of multiple sclerosis (MS) or other demyelinating disease&#xD;
             and/or Lambert-Eaton syndrome (paraneoplastic syndrome)&#xD;
&#xD;
          9. Patients with clinically significant cardiac disease including, but not limited to,&#xD;
             any of the following:&#xD;
&#xD;
               1. Myocardial infarction ≤ 6 months prior to first dose&#xD;
&#xD;
               2. Unstable angina pectoris&#xD;
&#xD;
               3. Uncontrolled congestive heart failure (New York Heart Association &gt; class II)&#xD;
&#xD;
               4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)&#xD;
&#xD;
               5. Uncontrolled cardiac arrhythmias&#xD;
&#xD;
         10. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
         11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)&#xD;
&#xD;
         12. Patients with a previous clinical diagnosis of noninfectious interstitial lung disease&#xD;
             (ILD), including noninfectious pneumonitis&#xD;
&#xD;
         13. Patients requiring use of folate-containing supplements (eg, folate deficiency)&#xD;
&#xD;
         14. Patients with prior hypersensitivity to monoclonal antibodies (mAb)&#xD;
&#xD;
         15. Women who are pregnant or breastfeeding&#xD;
&#xD;
         16. Patients who received prior treatment with MIRV or other FRα-targeting agents&#xD;
&#xD;
         17. Patients with untreated or symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
         18. Patients with a history of other malignancy within 3 years prior to enrollment.&#xD;
&#xD;
             Note: patients with tumors with a negligible risk for metastasis or death (eg,&#xD;
             adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or&#xD;
             carcinoma in situ of the cervix or breast) are eligible&#xD;
&#xD;
         19. Prior known hypersensitivity reactions to study drugs and/or any of their excipients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Method, MPH, MBA</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Matulonis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Coleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The US Oncology Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates (cCARE)</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Health Care System</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Panhandle</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Sudarshan K. Sharma, Ltd.</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Gynecologic Oncology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Oncology Associates/Sarah Cannon</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Hope</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute / Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - The Woodlands, Gynecologic Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin Department of Obstetrics &amp; Gynecology</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Care</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula and South Eastern Haematology &amp; Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc - lnstitut Roi Albert II</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur/Site Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>B5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Serdika&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <state>Prague</state>
        <zip>128 51</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMG Frauenklinik Robert-Koch-Str. 40</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEM</name>
      <address>
        <city>Essen</city>
        <zip>45135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <state>Munster</state>
        <zip>T12 DC4A</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <state>Munster</state>
        <zip>T12 DV56</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <state>Munster</state>
        <zip>X91ER8E</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>PO Box 9601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical center</name>
      <address>
        <city>Jerusalem</city>
        <zip>POB 12000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Santaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Candiolo</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro di Catania</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca'Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori- G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>6129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Przychodnia Lekarska Medicus</name>
      <address>
        <city>Chorzów</city>
        <state>Silesia</state>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazurskim Centrum Onkologiiw Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <state>Warmińsko-Mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Łódź</city>
        <state>Łódzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Castellana</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera - Complejo Hospitalario Universitario A Coruna</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>lnstitut Catala d' Oncologia L' Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia de Cordoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncología de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum resistant</keyword>
  <keyword>Folate-receptor alpha expression</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>mirvetuximab soravtansine</keyword>
  <keyword>IMGN853</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>MIRV</keyword>
  <keyword>FRα</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

